CUMYL-PICA
From Wikipedia, the free encyclopedia
 |
|
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C23H28N2O |
| Molar mass | 348.49 g/mol |
| 3D model (Jmol) | |
|
|
|
|
CUMYL-PICA (SGT-56) is an indole-3-carboxamide based synthetic cannabinoid. It is the α,α-dimethylbenzyl analogue of SDB-006.[1] It was briefly sold in New Zealand during 2013 as an ingredient of at the time legal synthetic cannabis products, but the product containing CUMYL-BICA and CUMYL-PICA was denied an interim licensing approval under the Psychoactive Substances regulatory scheme, due to reports of adverse events in consumers.[2] CUMYL-PICA acts as a potent agonist for the cannabinoid receptors, with approximately 20x selectivity for CB1, having an EC50 of 0.66nM for human CB1 receptors and 13nM for human CB2 receptors.[3]
See also[edit]
References[edit]
- ^ "CUMYL-PICA". Cayman Chemical. Retrieved 8 July 2015.
- ^ The Risk Assessment Score Table. New Zealand Ministry of Health, 27 September 2013
- ^ Bowden; et al. (11 April 2013). "Patent WO 2014167530 - Cannabinoid compounds". New Zealand Patent application 623626. Retrieved 11 July 2015.
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
